283 related articles for article (PubMed ID: 20493605)
1. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease.
Fassett RG; Gobe GC; Peake JM; Coombes JS
Am J Kidney Dis; 2010 Oct; 56(4):728-42. PubMed ID: 20493605
[TBL] [Abstract][Full Text] [Related]
2. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Donadio JV; Bergstralh EJ; Bibus DM; Grande JP
Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease.
Harper CR; Jacobson TA
Am J Cardiol; 2005 Dec; 96(11):1521-9. PubMed ID: 16310434
[TBL] [Abstract][Full Text] [Related]
4. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie CJ; Milani RV; Mehra MR; Ventura HO
J Am Coll Cardiol; 2009 Aug; 54(7):585-94. PubMed ID: 19660687
[TBL] [Abstract][Full Text] [Related]
6. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[TBL] [Abstract][Full Text] [Related]
7. How relevant is the ratio of dietary n-6 to n-3 polyunsaturated fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study.
Griffin BA
Curr Opin Lipidol; 2008 Feb; 19(1):57-62. PubMed ID: 18196988
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension.
Russo C; Olivieri O; Girelli D; Azzini M; Stanzial AM; Guarini P; Friso S; De Franceschi L; Corrocher R
J Hypertens; 1995 Dec; 13(12 Pt 2):1823-6. PubMed ID: 8903660
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
10. Effects of dietary polyunsaturated fatty acid supplementation in early renal insufficiency in dogs.
Brown SA; Brown CA; Crowell WA; Barsanti JA; Kang CW; Allen T; Cowell C; Finco DR
J Lab Clin Med; 2000 Mar; 135(3):275-86. PubMed ID: 10711867
[TBL] [Abstract][Full Text] [Related]
11. Highly purified omega-3 polyunsaturated fatty acids in clinical development.
Vik H
Herz; 2006 Dec; 31 Suppl 3():83-95. PubMed ID: 17575810
[TBL] [Abstract][Full Text] [Related]
12. Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders.
Assisi A; Banzi R; Buonocore C; Capasso F; Di Muzio V; Michelacci F; Renzo D; Tafuri G; Trotta F; Vitocolonna M; Garattini S
Int Clin Psychopharmacol; 2006 Nov; 21(6):319-36. PubMed ID: 17012979
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 fatty acid supplementation in advanced kidney disease.
Friedman AN
Semin Dial; 2010; 23(4):396-400. PubMed ID: 20701719
[TBL] [Abstract][Full Text] [Related]
14. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.
Masterton GS; Plevris JN; Hayes PC
Aliment Pharmacol Ther; 2010 Apr; 31(7):679-92. PubMed ID: 20415840
[TBL] [Abstract][Full Text] [Related]
15. Modulation of inflammatory cytokines by omega-3 fatty acids.
Kang JX; Weylandt KH
Subcell Biochem; 2008; 49():133-43. PubMed ID: 18751910
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain.
Goldberg RJ; Katz J
Pain; 2007 May; 129(1-2):210-23. PubMed ID: 17335973
[TBL] [Abstract][Full Text] [Related]
17. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
18. ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.
Liu LL; Wang LN
Clin Nephrol; 2012 Feb; 77(2):119-25. PubMed ID: 22257542
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids in the prevention-management of cardiovascular disease.
Simopoulos AP
Can J Physiol Pharmacol; 1997 Mar; 75(3):234-9. PubMed ID: 9164707
[TBL] [Abstract][Full Text] [Related]
20. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study.
Pettersson EE; Rekola S; Berglund L; Sundqvist KG; Angelin B; Diczfalusy U; Björkhem I; Bergström J
Clin Nephrol; 1994 Apr; 41(4):183-90. PubMed ID: 8026109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
